weekly the evolution of serum lipid concen- with anabolic steroid use. We also saw depression of apo A-I by 84% and 91%, and lipoprotein(a) decreased to undetectable amounts in both cases. These effects were reversed 10 weeks after the end of the steroid cycle in subject 1, but subject 2 still presented abnormal concentrations of serum lipids 13 weeks after drug cessation. The periods until reversibility of anabolic steroid effects on lipids were longer than those reported in previous studies.
Evolution of serum lipids in two male bodybuilders using anabolic steroids Fi 
Matenais and Methods

SUBJECTS
Subject 1, a 25-year-old
man, underwent four anabolic cycles in the 2 years preceding this study, the last one ending 9 months earlier. Subject 2, a 29-year-old man, had undergone -18-20 anabolic cycles in the previous 8 years, the last one ending 5 months before the beginning of this study. Both subjects were nonsmokers and did not consume any alcohol. They presented with normal liver, kidney, and hematologic function. During our study, subjects 1 and 2 followed AS cycles of 7 and 8 weeks, respectively.
We informed them of all the risks they were taking by using these drugs. As reported in a written protocol by both subjects, the drugs they used were: week throughout the study, were high in protein, --300 g/day, and low in fat, -60 g/day (-5000 kcal/day for subject 1 and 6500 kcal/day for subject 2). Subject 2 began another steroid cycle on week 14 after the end of his preceding cycle, though he was strongly advised not to do so.
PROCEDURES
Serum aliquots (1 mL) from each subject were processed as indicated by Bachorik [6] . For sequential ultracentrifugation of lipoprotein [7, 8] The maximum increases of LDL-C in our two cases, 144%
and 156%, are far greater than the ones described previously. Only two studies [12, 15] of subjects with high total AS dose regiments presented LDL-C increases close to ours; in one [12] , although the mean increase was 61%, one of their figures showed four subjects whose LDL-C values were comparable with those in our study. In four studies with low AS doses, their weighted average increase in LDL-C was 20% (range, 11-29%) [3] . These facts suggest that a dose relationship between AS and LDL-C concentrations may be possible, but no study has seriously addressed this question.
In five previous studies, the apo A-I decreased between 33%
and 41% [3] , whereas our two cases showed maximum decreases of 84% and 91%. The difference in HDL-C decrease between these studies and ours was similar but smaller. Only two studies have reported changes in apo B, one noting a 35% increase [10] and the other a 24% decrease [17] . In the former, although the mean increase is very far from our maximum increases (134% and 156%), the SD for the apo B measurements is considerable, and probably the results for some of their cases are closer to ours.
Lp(a) decreases associated with stanozolol [17] and danazol [5] have been previously described.
The mechanism for this decrease is unknown. Carlson et al. [18] reported that nicotinic acid produces a decrease in Lp(a) that is strongly correlated with a reduction in LDL-C. Obviously, this parallel course does not happen with AS, which suggests the action of different mechanisms in the metabolic control of these lipoproteins.
The main goal of our work was to investigate the time to normalization of HDL-C concentrations after an AS cycle. Data in previous studies reported that HDL-C concentrations fell near the minimum value in the first week after the beginning of AS use and returned to pretreatment values 3 to 5 weeks after stopping the drug use [3] .Our two cases suggest, at leastfor subjects taking high AS doses, a much longer time for reversibility of AS effects on serum lipids. Glazer and Suchman also suggested this in a recent study but showed no data [4] . Although subject 1 returned to pretreatment concentrations of lipids 10 weeks after the end of AS use, subject 2 was very far from his pretreatment values 13 weeks after the end of drug cessation; however, subject 2 had been an AS user for 6 years more than subject 1. It would be interesting to investigate whether prolonged AS use has any residual effect on the capacity to reverse the lipid alterations induced by these drugs. After the end of the AS cycle, subject 2 needed 3 more weeks than subject 1 to recover measurable Lp(a) concentrations; we do not know whether this slower regaining is associated with a slower recovery of HDL-C in other persons using AS.
One point that remains unclear is why the HDL-C decrease and LDL-C increase were greatest in our cases at about week 5 of the cycle, when the highest AS doses are just beginning.
Evaluating the contribution of AS use to coronary heart disease risk is very complicated [3] but must be considered very seriously. Most AS users, unfortunately, are not aware of this potential risk. If the time to recover pretreatment concentrations of serum lipids is longer than previously thought, this might imply a greater AS-associated risk of coronary heart disease.
